Five Stocks To Buy According To Top Biotech-Focused Funds
Biotechnology is a very interesting industry to invest in, but also very complex.
Posts Tagged ‘Julian Baker’
The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
Baker Bros. Advisors has arguably been the most successful healthcare-focused hedge fund on the Street in recent years.
Aquinox Pharmaceuticals Inc (AQXP): Baker Bros. Advisors Pushes Stake to Over 45%
A newly-amended 13D filing with the Securities and Exchange Commission revealed that Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) has signed an Underwriting Agreement with Leerink...
Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares
Julian Baker and Felix Baker's Baker Bros.
Billionaire Leone Boosts Stake in This REIT, Ubben Sells More Shares of Motorola Solutions Inc. (MSI), Plus Two Other Hot Moves
It is generally believed that individuals seeking to become millionaires (and who isn't?) need to think and act like millionaires.
Seattle Genetics Inc (SGEN): Baker Bros. Keeps Buying Shares
Seattle Genetics Inc. (NASDAQ:SGEN) is the subject of a new 13D filing issued by Julian Baker and Felix Baker‘s Baker Bros. Advisors.
Healthcare-focused Baker Bros. Advisors’ Top Picks: Incyte, Alexion, ACADIA & More
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
13D Filing: Baker Bros. Advisors Buys More Shares of Seattle Genetics Inc (SGEN)
Seattle Genetics Inc. (NASDAQ:SGEN) is the subject of a new 13D filing issued by Julian Baker and Felix Baker's Baker Bros.
Top 5 Healthcare Bets of World-Class Baker Bros. Advisors
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
Elite Hedge Funds Make Bigger Moves Into These 2 Stocks
Neal C. Bradsher's Broadwood Capital revealed in a recent Form 4 filing with the SEC that it has purchased an additional 2.43 million shares of BioTime, Inc.
Baker Bros. Relentlessly Adding Shares Of One Biotech, Going Activist On Another
Julian Baker and Felix Baker’s Baker Bros. Advisors continues to relentlessly add shares to its position in Seattle Genetics, Inc. (NASDAQ:SGEN).
Don’t Miss White-Hot Baker Bros.’ New Healthcare Picks
At Insider Monkey, we track over 700 hedge funds and investment companies, which allows us to understand the market sentiment towards any given stock. Baker Bros.
Another Score For Baker Bros. As Anacor Pharmaceuticals Inc (ANAC) Soars 65% Premarket On Crisaborole Trial Success
Shares of Anacor Pharmaceuticals Inc (NASDAQ:ANAC) soared to a lofty $140.00 per share pre-market high today, or a whopping 65.47% higher than the stock’s closing price of $...
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns
With the rapid pace of M&A happening in the biotechnology sector, Julian Baker and Felix Baker's Baker Bros. Advisors is making a habit of hitting home runs in 2015.
Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY) Among Fund’s Other Top Picks
Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.
Mirati Therapeutics Inc. (MRTX): Baker Bros. Advisors Increases Stake in Growing Stock
Julian Baker and Felix Baker’s Baker Bros. Advisors recently disclosed an increase of around 929,700 shares to its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Tekmira Pharmaceuticals Corporation (TKMR): Falcon Edge Capital Discloses 10% Passive Stake
Another one of the funds we track here at Insider Monkey has made a big move into Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), as it was revealed in a filing that Richard...
Tekmira Pharmaceuticals Corporation (TKMR): RA Capital Management Discloses 10% Passive Stake
It was revealed in a filing yesterday with the U.S Securities and Exchange Commission that RA Capital Management has opened a large, passive position in Tekmira Pharmaceuticals...
Bellicum Pharmaceuticals Inc (BLCM): Baker Bros. Discloses 16% Passive Stake
As a new filing with the Securities and Exchange Commission showed, Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has been added to the equity portfolio of Julian and Felix Bakers...
Vanda Pharmaceuticals Inc (VNDA): Deerfield Management Increases Exposure Following Positive Announcement
James Flynn’s Deerfield Management disclosed an increase in its stake in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) on Friday.
Seattle Genetics Inc. (SGEN), Cerus Corporation (CERS): Baker Bros. Advisors’ Latest Moves
Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday.
Deerfield Management Ups Stake in Aerie Pharmaceuticals Inc (AERI)
In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Triumph Group Inc (TGI), Intercept Pharmaceuticals Inc (ICPT), Zynga Inc (ZNGA): Viking Global’s Top 5 Small-Cap Picks
Small-cap picks from individual funds might provide investors with attractive investment options.
Felix Baker Raises Stake in Synageva BioPharma Corp (GEVA) Through Convention of Options
As a new form 4 filing with the Securities and Exchange Commission showed, Julian and Felix Bakers' Baker Bros Advisors, a fund focused on the biotechnology and healthcare companies...
Baker Bros Reveals New Stake in Aquinox Pharmaceuticals (AQXP)
In a new filing with the SEC, Julian Baker and Felix Baker’s Baker Bros. Advisors revealed new stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).
Baker Bros. Advisors’ Latest Moves Involve Genomic Health, Inc. (GHDX), & Celsus Therapeutics PLC (ADR) (CLSXD)
Julian Baker and Felix Baker's Baker Bros. Advisors have disclosed in a new filing with the SEC adding approximately 4,100 shares to their stake in Genomic Health, Inc.
Five Hedge Fund Moves in Healthcare Sector From This Week
The healthcare sector is usually very attractive to investors, since the companies involved in it have a great potential to grow.
The Baker Brothers Cut Their Position in Incyte Corporation
Julian and Felix Baker and their hedge fund, Baker Bros.
Baker Bros. Decreases Exposure at Viropharma
Julian and Felix Baker's hedge fund, Baker Bros.
Baker Bros. Advisors Sells Some MEI Pharma, Discloses a Massive Stake in Mirati Therapeutics
In a couple 13D filings with the SEC, Julian and Felix Baker's Baker Bros. Advisors reported a 19.9% stake in Mirati Therapeutics, Inc.
Baker Bros. Buy Some Shares of Mirati Therapeutics
Baker Bros., Mirati Therapeutics: In a new form 4 from today, Julian and Felix Baker's Baker Bros. Advisors reported buying 400,000 shares of Mirati Therapeutics, Inc.
Is Synageva BioPharma a Buy? Baker Bros. Thinks So
Is Synageva BioPharma a buy? Baker Bros.
Biotech-Focused Hedge Fund is Bullish on ChemoCentryx Inc (CCXI)
Tracking the activity of hedge funds via their filings with the Securities and Exchange Commission is particularly crucial, since these filings reveal the latest moves made by...
What Hedge Funds Think About Kythera Biopharmaceuticals Inc (KYTH)
To the average investor, there are tons of methods market participants can use to track publicly traded companies.
Hedge Fund Bets On Onyx Pharmaceuticals, Inc. (ONXX)
As fast as we can type this, Phill Gross and Robert Atchinson's hedge fund, Adage Capital Partners, disclosed ownership of about 3.7 million shares of Onyx Pharmaceuticals, ...
Do Hedge Funds and Insiders Love Halozyme Therapeutics, Inc. (HALO)?
Now, according to many investors, hedge funds are seen as delayed, outdated financial tools of an era lost to time.
Repros Therapeutics Inc (RPRX): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
To many of your peers, hedge funds are viewed as bloated, outdated financial vehicles of a forgotten age.
Is XenoPort, Inc. (XNPT) Going to Burn These Hedge Funds?
At the moment, there are plenty of metrics market participants can use to monitor the equity markets.
What Hedge Funds Think About ArQule, Inc. (ARQL)
In the 21st century investor’s toolkit, there are many metrics shareholders can use to monitor stocks.
Hedge Funds Are Selling Threshold Pharmaceuticals, Inc. (THLD)
At the moment, there are tons of methods market participants can use to watch Mr. Market. A pair of the most useful are hedge fund and insider trading sentiment.
InterMune Inc (ITMN): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
To many market players, hedge funds are perceived as delayed, old financial tools of a period lost to current times.
What Hedge Funds Think About Genomic Health, Inc. (GHDX)
In the 21st century investor’s toolkit, there are plenty of indicators investors can use to monitor stocks. Some of the best are hedge fund and insider trading movement.
QLT Inc. (USA) (QLTI): Are Hedge Funds Right About This Stock?
In the financial world, there are many indicators shareholders can use to analyze Mr. Market. A pair of the most innovative are hedge fund and insider trading activity.
Incyte Corporation (INCY): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the 21st century investor’s toolkit, there are many gauges shareholders can use to track their holdings.
Viropharma Inc (VPHM): Are Hedge Funds Right About This Stock?
If you were to ask many traders, hedge funds are seen as useless, old investment vehicles of an era lost to time.
Auxilium Pharmaceuticals, Inc. (AUXL): Are Hedge Funds Right About This Stock?
To many of your fellow readers, hedge funds are assumed to be useless, old investment vehicles of a period lost to current times.
What Hedge Funds Think About Pharmacyclics, Inc. (PCYC)
In today’s marketplace, there are many metrics market participants can use to track publicly traded companies.
This Metric Says You Are Smart to Sell Ariad Pharmaceuticals, Inc. (ARIA)
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Onyx Pharmaceuticals, Inc. (ONXX) Investors: Listen Up
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
